Recently, there is a good news in our WuHan YZY biopharmaceutical co.LTD. The application for expanded patented protection which owned hard core patented technology BISPECIFIC ANTIBODY (Pat Nos. US 9562110) has been approved in USA (Pat Nos. US9562110, Authorized Date: Feb 7th 2017). After obtaining the expanded patented protection, our company has owned the protections of the CD3-based technology platform, and other 35 tumor drug targets containing breast cancer, liver cancer, leukemia and so on. Doc. Pengfei Zhou, the patent first inventor who is the chief scientists in our company said: the wide range of this patent licensing could cover the vast majority of known drug targets.This event creates a new situation for innovation drug research in the tumor area. It’s a milestone of new stage in Chinese biopharmaceutical technology. Furthermore,it brings new hope to the masses of cancer patients.
Bispecific antibody is of a crucial research and development direction for the next generation of therapeutic antibodies. As a leading enterprise in the field of developing bispecific antibody in China,YZYBIO has successfully developed a series of bispecific antibody productsthrough this patented technology. These two products, anti-Her2×CD3 bispecific antibody and the anti-Epcam×CD3 bispecific antibody, have gained support from national 12th Five-Year significant new drugs creation special science and technology major in 2014,2015 successively. We are the first company to submit a new drug registration application to CDE( CENTER FOR DRUG EVALUATION and enter the review stage. These two drugs aimed to be used in treatment of breast cancer, gastric cancer,ovarian cancer, malignancy and tumor ascites ( especially in ovarian cancer,colorectal cancer, liver cancer, and cancer ascites ).
YZYBIO adheres to the principle: Root life, answer cancer. We depend on innovation to develop new technologies, new targets and new products. We will vigorously promote the development of cancer drugs and safeguard human health!